Recombinant Human Sentrin-specific protease 2_SENP2
- Known as:
- Recombinant Human Sentrin-specific protease 2_SENP2
- Catalog number:
- CH01
- Product Quantity:
- 10 ug
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Recombinant Human Sentrin-specific protease 2_SENP2
Related genes to: Recombinant Human Sentrin-specific protease 2_SENP2
- Gene:
- HTRA1 NIH gene
- Name:
- HtrA serine peptidase 1
- Previous symbol:
- PRSS11
- Synonyms:
- HtrA, IGFBP5-protease, ARMD7
- Chromosome:
- 10q26.13
- Locus Type:
- gene with protein product
- Date approved:
- 1997-07-25
- Date modifiied:
- 2016-10-05
Related products to: Recombinant Human Sentrin-specific protease 2_SENP2
Related articles to: Recombinant Human Sentrin-specific protease 2_SENP2
- A growing number of target antigens have been identified in membranous nephropathy (MN) in recent years. Clinical correlations exist for some MN antigens, whereas others remain poorly characterized because of their rarity. High-temperature requirement A serine peptidase 1 (HTRA1) is the target antigen in approximately 1%-2% of MN cases without any established disease associations. Recent studies suggest HTRA1-MN may associate with malignancies in approximately 12% of cases, mostly solid tumors. To date, only 2 cases of HTRA1-MN have been reported in the setting of atypical hematopoietic disorders, including chronic lymphocytic lymphoma and monoclonal gammopathy of uncertain significance. Here, we present a case of HTRA1-MN with polytypic IgG deposits in a 62-year-old man with a plasma cell dyscrasia (IgA monoclonal gammopathy and 20% bone marrow involvement by a λ-restricted plasma cell neoplasm) who presented with nephrotic syndrome. A limited initial kidney biopsy suggested early MN. Daratumumab-based induction therapy resulted in a partial renal response (urinary protein-creatinine ratio of 0.7 g/g). However, proteinuria subsequently recurred (∼6.7 g/g), prompting a repeat biopsy that demonstrated HTRA1-MN with polytypic IgG staining. Proteinuria has progressively worsened (12 g/g), with persistent minimal residual plasma cell disease despite ongoing daratumumab maintenance therapy. To our knowledge, this case represents only the second reported case of HTRA1-MN occurring in the setting of monoclonal gammopathy, the first in multiple myeloma, and a rare example of a nonmonotypic MN in this context. Temporal proximity and partial response to anti-plasma cell therapy suggest a possible paraneoplastic relationship, although a causal relationship remains unproven. - Source: PubMed
Publication date: 2026/05/12
Zuckerman Jonathan ELarson SarahAbdelnour Lama - Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a considerable risk of recurrence, but reliable predictive markers are limited. High-temperature requirement A serine peptidase 1 (HtrA1) has been implicated in the progression of several cancers and may also play a role in GCTB recurrence. - Source: PubMed
Publication date: 2026/06/12
Mirioglu AkifDalkir Kaan AliGokmen Mehmet YigitBagir MelihAtes Kivilcim ErenDeveci Mehmet AliGönlüşen GülfilizOzbarlas Hilmi Serdar - Migraine is a highly prevalent, heritable neurological disorder with a marked female predominance, indicating substantial hormonal contributions to disease pathophysiology. Endocrine-disrupting chemicals (EDCs) are ubiquitous environmental contaminants that interfere with hormonal signaling and have been linked to multiple diseases, yet their molecular contribution to migraine remains unclear. This study aims to identify EDC-related genes contributing to migraine risk and explore underlying mechanisms using an integrative multi-omics and causal inference framework. - Source: PubMed
Publication date: 2026/06/08
Ren YinfanXu ZiqiXu ZifeiZhang GuifangHuang HuanjieWang ChuhuaiHu Xiao-Qian - Ischemic cardiomyopathy (ICM), a leading cause of heart failure, is characterised by complex cellular heterogeneity and a dysregulated microenvironment. A systematic computational dissection of its molecular mechanisms and a coherent pipeline from discovery to potential therapeutics is currently lacking. We integrated single-cell RNA sequencing (scRNA-seq) data from ICM patients with four independent bulk transcriptomic cohorts. A cardiac cellular atlas was constructed, and candidate genes were filtered through differential expression analysis. Subsequently, a benchmark of 127 machine learning algorithm-feature selection combinations was performed to identify robust diagnostic hub genes. Their functions were validated at single-cell resolution via UCell scoring, pseudotime trajectory analysis, and virtual knockout perturbations using scTenifoldKnk. The immune infiltration landscape was assessed using CIBERSORT and MCP-counter. Finally, computational drug repositioning and molecular docking were employed to screen for potential compounds targeting the hub genes. Machine learning identified a core 5-gene signature (NPPA, HTRA1, LUM, ASPN, and OGN) demonstrating excellent diagnostic performance across independent datasets (AUC > 0.83). Single-cell analysis revealed that these genes were most abundantly expressed in fibroblasts and were consistently upregulated in ICM. Pseudotemporal trajectory analysis illustrated their dynamic expression patterns. Virtual knockout and functional enrichment indicated that four of these genes (ASPN, HTRA1, LUM, OGN) significantly perturbed pathways related to the regulation of inflammatory response. Immune profiling revealed increased infiltration of fibroblasts and plasma cells in ICM. Molecular docking identified the compound LDN-193189 as a potential lead molecule with high predicted binding affinity (binding energy < -9 kcal·mol) for ASPN, LUM, and OGN. Through multi-omics integration and computational biology, this study systematically delineates a fibroblast-centric molecular network involving key hub genes and an altered immune microenvironment in ICM and computationally proposes a potential therapeutic candidate. These findings provide a crucial computational foundation and experimental direction for understanding ICM pathology and developing novel therapeutic strategies. - Source: PubMed
Yu GaoxiuKan TongShen JianZhang YanmingWang CongGuo ZhifuChen Feng - Patients with heart failure (HF) frequently develop atrial fibrillation, but the precise molecular mechanisms are unclear, leading to limited therapeutic strategies. - Source: PubMed
Publication date: 2026/06/06
Nian SiqiZhao LuluHe XiaokangXia PingLiu YanqingHua BaotongLi JunZhang Hongxing